logo

  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Myocardial Ischemia Market, By Type (Asymptomatic, Symptomatic), By Treatment (ECG, and Antiplatelet Agents), By End User (Hospitals & Clinics, Ambulatory Surgical Centres, Diagnostic Centres) opportunities and forecast 2020-2027

  • DLR2177
  • 19 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Myocardial ischemia is categorised as a specific condition, which includes insufficient flow of the blood to heart muscle through the coronary arteries. Due to block or constriction of arteries, heart is not able to drive oxygenated blood, and various other vital nutrients to body efficiently and hence results into destruction of heart muscles. High prevalence of coronary heart diseases, changing lifestyles and increasing cases of diabetes, are the major factors leading to the market demand during the forecast period. Furthermore, the development of drugs including vorapaxar, heparin, and others are expected to bring relief to the patients from disease. However, the side-effects of the drugs are expected to hinder the market growth.
Market shows the high growth potential in coming year owing to the continuously increasing stress environment. On the other hand some of the risk factors such as obesity, high blood pressure, diabetes, high blood triglyceride level, tobacco, high blood cholesterol level, tobacco, waist circumference, tobacco, and lack of physical activity are further expected to restrain the market growth. Apart from this, other complications include heart failure, irregular heart rhythm, and heart attack.

Segment Overview

By type, the market is segmented as asymptomatic and symptomatic. The asymptomatic myocardial ischemia segment commanded the largest market share in 2018. The family history of heart diseases, growing number of smokers, and incidence of cases of high cholesterol and blood pressure, and sedentary lifestyle are driving growth in the segment.
Additionally, the treatment segment is segmented into medications (antiplatelet agents) and surgery (ECG). The antiplatelet segment has gained substantial traction owing to the increasing prevalence of the coronary heart disease and also as the large population living a stressful lifestyle.

Regional Overview

Geographically, North-American region holds the major share, followed by the European region in the myocardial ischemia market due to the rise in awareness about the cardiovascular diseases (CVD), rise in competition from the small market players and due to the increasing technological advancements in the region. According to survey, about 1.5 million cases of the diseases occur annually in the U.S.
Asian-Pacific region is anticipated to witness the higher growth rate owing to increase in prevalence of heart-related diseases and constant development in the economies during the forecast period. It is expected that future will provide more opportunities on account of the presence of well-developed healthcare sector and increasing patient population in coming years.

Competitor overview

The key companies operating in the market includes Taxus Cardium, ViroMed Co. Ltd, Daiichi Sankyo Company Limited, Edwards Lifesciences Corporation, Merck KGaA, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Novartis AG, Bayer AG, Johnson & Johnson Services Inc. (Janssen Global Services LLC), AstraZeneca, Atrium Medical Corporation, Vasade Biosciences, Inc., Pfizer Inc., Baxter International, Inc. The pharmaceutical companies are repeatedly trying to come up with new therapeutic developments or products for the treatment of the disease.
For instance; AstraZeneca will develop its Global Medicines Development (GMD) division in Bengaluru, India. The site will be one of the nine global sites which will support the monitor safety, efficacy, clinical trials, and other regulatory management essential for a product’s lifecycle.

Key Players
  1. Taxus Cardium
  2. ViroMed Co. Ltd
  3. Daiichi Sankyo Company Limited
  4. Edwards Lifesciences Corporation
  5. Merck KGaA
  6. Boston Scientific Corporation
  7. Boehringer Ingelheim International Gmbh
  8. Novartis AG, Bayer AG
  9. Johnson & Johnson Services Inc. (Janssen Global Services LLC)
  10. AstraZeneca
  11. Atrium Medical Corporation
  12. Vasade Biosciences, Inc.
  13. Pfizer Inc.
  14. Baxter International, Inc.

Market Segmentation

By Type
  • Asymptomatic,
  • Symptomatic
By Treatment
  • ECG
  • Antiplatelet Agents
By End User
  • Hospitals & Clinics
  • Ambulatory Surgical Centres
  • Diagnostic Centre
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 13

    2 Market Introduction 15

    • 2.1 Introduction 16
    • 2.2 Assumptions & Limitations 16

    3 Research Methodology 18

    • 3.1 Research Process 19
    • 3.2 Primary Research 19
    • 3.3 Secondary Research 20
    • 3.4 Market Size Estimation 20

    4 Market Dynamics 21

    • 4.1 Introduction 22
    • 4.2 Drivers 23
      • 4.2.1 High prevalence of coronary heart disease 23
      • 4.2.2 Rising prevalence of diabetes 23
      • 4.2.3 Lifestyle changes 23
      • 4.2.4 Drivers Impact Analysis 23
    • 4.3 Restraints 24
      • 4.3.1 High cost of therapeutic surgeries 24
      • 4.3.2 Side effects related to medications 24
      • 4.3.3 Restraints Impact Analysis 24
    • 4.4 Opportunity 25
      • 4.4.1 Untapped markets of the Asia Pacific region 25
    • 4.5 Macroeconomic Indicator 25

    5 Market Factor Analysis 26

    • 5.1 Value Chain Analysis 27
      • 5.1.1 R&D and Designing 27
      • 5.1.2 Manufacturing 27
      • 5.1.3 Distribution & Sales 27
      • 5.1.4 Post-Sales Review 28
    • 5.2 Porter’s Five Forces Model 28
      • 5.2.1 Bargaining Power of Suppliers 28
      • 5.2.2 Bargaining Power of Buyers 29
      • 5.2.3 Threat of New Entrants 29
      • 5.2.4 Threat of Substitutes 29
      • 5.2.5 Intensity of Rivalry 29
    • 5.3 Investment Opportunities 29
    • 5.4 Pricing Analysis 30
    • 5.5 Demand & Supply: Gap Analysis 30

    6 Global Myocardial Ischemia Market, by Type 31

    • 6.1 Introduction 32
    • 6.2 Symptomatic 33
    • 6.3 Asymptomatic 33

    7 Global Myocardial Ischemia Market, by Treatment & Diagnosis 34

    • 7.1 Introduction 35
    • 7.2 Diagnosis 37
    • 7.3 Treatment 37

    8 Global Myocardial Ischemia Market, by End User 38

    • 8.1 Introduction 39
    • 8.2 Hospitals & Clinics 40
    • 8.3 Diagnostic Centers 40
    • 8.4 Ambulatory Surgery Centers 40

    9 Global Myocardial Ischemia Market, by Region 41

    • 9.1 Introduction 42
    • 9.2 Americas 43
      • 9.2.1 North America 46
        • 9.2.1.1 U.S. 48
        • 9.2.1.2 Canada 50
      • 9.2.2 South America 52
    • 9.3 Europe 55
      • 9.3.1 Western Europe 58
        • 9.3.1.1 Germany 60
        • 9.3.1.2 France 62
        • 9.3.1.3 U.K 64
        • 9.3.1.4 Italy 66
        • 9.3.1.5 Spain 68
        • 9.3.1.6 Rest of Western Europe 70
      • 9.3.2 Eastern Europe 72
    • 9.4 Asia Pacific 75
      • 9.4.1 Japan 78
      • 9.4.2 China 80
      • 9.4.3 India 82
      • 9.4.4 Australia 84
      • 9.4.5 Republic of Korea 86
      • 9.4.6 Rest of Asia Pacific 88
    • 9.5 Middle East & Africa 91
      • 9.5.1 United Arab Emirates 94
      • 9.5.2 Saudi Arabia 96
      • 9.5.3 Oman 98
      • 9.5.4 Kuwait 100
      • 9.5.5 Qatar 102
      • 9.5.6 Rest of The Middle East & Africa 105

    10 Competitive Landscape 108

    • 10.1 Introduction 109

    11 Company Profiles 110

    • 11.1 Taxus Cardium 111
      • 11.1.1 Company Overview 111
      • 11.1.2 Financial Overview 111
      • 11.1.3 Products Offering 111
      • 11.1.4 Key Developments 111
      • 11.1.5 SWOT Analysis 111
      • 11.1.6 Key Strategy 111
    • 11.2 ViroMed Co. Ltd. 112
      • 11.2.1 Company Overview 112
      • 11.2.2 Financial Overview 112
      • 11.2.3 Products Offering 113
      • 11.2.4 Key Developments 113
      • 11.2.5 SWOT Analysis 113
      • 11.2.6 Key Strategy 113
    • 11.3 Edwards Lifesciences Corporation 114
      • 11.3.1 Company Overview 114
      • 11.3.2 Financial Overview 114
      • 11.3.3 Products Offering 115
      • 11.3.4 Key Developments 115
      • 11.3.5 SWOT Analysis 115
      • 11.3.6 Key Strategy 115
    • 11.4 Daiichi Sankyo Company Limited 116
      • 11.4.1 Company Overview 116
      • 11.4.2 Financial Overview 116
      • 11.4.3 Products Offering 117
      • 11.4.4 Key Developments 117
      • 11.4.5 SWOT Analysis 117
      • 11.4.6 Key Strategy 117
    • 11.5 Boston Scientific Corporation 118
      • 11.5.1 Company Overview 118
      • 11.5.2 Financial Overview 118
      • 11.5.3 Products Offering 119
      • 11.5.4 Key Developments 119
      • 11.5.5 SWOT Analysis 119
      • 11.5.6 Key Strategy 119
    • 11.6 Merck KGaA 120
      • 11.6.1 Company Overview 120
      • 11.6.2 Financial Overview 120
      • 11.6.3 Products Offering 121
      • 11.6.4 Key Developments 121
      • 11.6.5 SWOT Analysis 121
      • 11.6.6 Key Strategy 121
    • 11.7 Novartis AG 122
      • 11.7.1 Company Overview 122
      • 11.7.2 Financial Overview 122
      • 11.7.3 Products Offering 123
      • 11.7.4 Key Developments 123
      • 11.7.5 SWOT Analysis 123
      • 11.7.6 Key Strategy 123
    • 11.8 Boehringer Ingelheim International GmbH 124
      • 11.8.1 Company Overview 124
      • 11.8.2 Financial Overview 124
      • 11.8.3 Products Offering 125
      • 11.8.4 Key Developments 125
      • 11.8.5 SWOT Analysis 125
      • 11.8.6 Key Strategy 125
    • 11.9 Johnson & Johnson Services Inc. (Janssen Global Services, LLC) 126
      • 11.9.1 Company Overview 126
      • 11.9.2 Financial Overview 126
      • 11.9.3 Products Offering 127
      • 11.9.4 Key Developments 127
      • 11.9.5 SWOT Analysis 127
      • 11.9.6 Key Strategy 127
    • 11.10 Bayer AG 128
      • 11.10.1 Company Overview 128
      • 11.10.2 Financial Overview 128
      • 11.10.3 Products Offering 129
      • 11.10.4 Key Developments 129
      • 11.10.5 SWOT Analysis 129
      • 11.10.6 Key Strategy 129
    • 11.11 AstraZeneca 130
      • 11.11.1 Company Overview 130
      • 11.11.2 Financial Overview 130
      • 11.11.3 Products Offering 131
      • 11.11.4 Key Developments 131
      • 11.11.5 SWOT Analysis 131
      • 11.11.6 Key Strategy 131
    • 11.12 Pfizer Inc. 132
      • 11.12.1 Company Overview 132
      • 11.12.2 Financial Overview 132
      • 11.12.3 Products Offering 133
      • 11.12.4 Key Developments 133
      • 11.12.5 SWOT Analysis 133
      • 11.12.6 Key Strategy 133

    12 Appendix 134

    Report You Might be Interested

    Keywords